Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Research and development of therapeutic mAbs: An analysis based on pipeline projects.

Literature DB >> 26211701

Research and development of therapeutic mAbs: An analysis based on pipeline projects.

Xiaomei Geng¹, Xiangjun Kong¹, Hao Hu¹, Jiayu Chen^2,3, Fengqing Yang⁴, Hongyu Liang¹, Xin Chen¹, Yuanjia Hu¹.

Abstract

As the subject of active research and development (R&D) in recent decades, monoclonal antibodies have emerged among the major classes of therapeutic agents for treatment of many human diseases, especially cancers, infections, and immunological disorders. This article surveys the landscape of R&D projects of therapeutic monoclonal antibodies (mAbs), which are mostly used for disease immunotherapy, from a number of perspectives, including therapeutic indications, development phases, participants, and citation of related patents. The results of this research can be used as a reference resource for pharmaceutical researchers, investors, and policymakers in the field of therapeutic mAbs.

Entities: Disease Species

Keywords: R&D; development trends; monoclonal antibody; patent citation network; pipeline projects; therapeutic application

Mesh：

Substances：
Antibodies, Monoclonal

Year: 2015 PMID： 26211701 PMCID： PMC4916486 DOI： 10.1080/21645515.2015.1074362

Source DB: PubMed Journal: Hum Vaccin Immunother ISSN： 2164-5515 Impact factor: 3.452

42 in total

Review 1. Development trends for human monoclonal antibody therapeutics.

Authors: Aaron L Nelson; Eugen Dhimolea; Janice M Reichert
Journal: Nat Rev Drug Discov Date: 2010-09-03 Impact factor: 84.694

Review 2. Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know.

Authors: Ian N Foltz; Margaret Karow; Scott M Wasserman
Journal: Circulation Date: 2013-06-04 Impact factor: 29.690

Review 3. The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.

Authors: Rinpei Niwa; Mitsuo Satoh
Journal: J Pharm Sci Date: 2015-01-12 Impact factor: 3.534

Review 4. Research and development of anti-Alzheimer's drugs: an analysis based on technology flows measured by patent citations.

Authors: Jiachen Xu; Xiangjun Kong; Lan Qiu; Xiaomei Geng; Yuanjia Hu; Yitao Wang
Journal: Expert Opin Ther Pat Date: 2014-05-05 Impact factor: 6.674

Review 5. Making antibodies by phage display technology.

Authors: G Winter; A D Griffiths; R E Hawkins; H R Hoogenboom
Journal: Annu Rev Immunol Date: 1994 Impact factor: 28.527

Review 6. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.

Authors: S Shak
Journal: Semin Oncol Date: 1999-08 Impact factor: 4.929

Review 7. Case studies on clinical evaluation of biosimilar monoclonal antibody: scientific considerations for regulatory approval.

Authors: Alex Kudrin; Ivana Knezevic; Jeewon Joung; Hye-Na Kang
Journal: Biologicals Date: 2014-11-29 Impact factor: 1.856

8. Characterizing the community structure of complex networks.

Authors: Andrea Lancichinetti; Mikko Kivelä; Jari Saramäki; Santo Fortunato
Journal: PLoS One Date: 2010-08-12 Impact factor: 3.240

Review 9. Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials.

Authors: Pernelle Lavaud; Fabrice Andre
Journal: BMC Med Date: 2014-08-12 Impact factor: 8.775

Review 10. Anti-infective monoclonal antibodies: perils and promise of development.

Authors: Janice M Reichert; Matthew C Dewitz
Journal: Nat Rev Drug Discov Date: 2006-03 Impact factor: 84.694

12 in total

1. Research and development of mAb drugs in China: a look from policy perspectives.

Authors: Rong Jiang; Yuanyuan Sun; Carolina Ung; Xinyue Dong; Xiangjun Kong; Yuanjia Hu; Rong Shao
Journal: Hum Vaccin Immunother Date: 2019-05-22 Impact factor: 3.452

2. Evolving patterns in a collaboration network of global R&D on monoclonal antibodies.

Authors: Xiangjun Kong; Jian-Bo Wan; Hao Hu; Shibing Su; Yuanjia Hu
Journal: MAbs Date: 2017-07-24 Impact factor: 5.857

3. Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.

Authors: Sai Kiran Sharma; Andrew Chow; Sebastien Monette; Delphine Vivier; Jacob Pourat; Kimberly J Edwards; Thomas R Dilling; Dalya Abdel-Atti; Brian M Zeglis; John T Poirier; Jason S Lewis
Journal: Cancer Res Date: 2018-01-23 Impact factor: 12.701

4. Patent trend and competitive analysis of cancer immunotherapy in the United States.

Authors: Chia-Lin Pan; Feng-Chi Chen
Journal: Hum Vaccin Immunother Date: 2017-11-02 Impact factor: 3.452

5. Trends involving monoclonal antibody (mAb) research and commercialization: A scientometric analysis of IMS Lifecycle R&D Focus Database (1980-2016).

Authors: Yunfeng Lai; Sizhuo Suo; Ruibing Wang; Xiangjun Kong; Yuanjia Hu; Daisheng Tang; Honghao Shi; Shengqi Chen; Hao Hu
Journal: Hum Vaccin Immunother Date: 2018-01-23 Impact factor: 3.452

6. Quantification of residual AEBSF-related impurities by reversed-phase liquid chromatography.

Authors: Cindy X Cai; Nicole A Schneck; Doug Harris; Daniel Blackstock; Vera B Ivleva; Kuang-Chuan Cheng; Adam Charlton; Frank J Arnold; Jonathan W Cooper; Q Paula Lei
Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2019-03-20 Impact factor: 3.205

Review 7. Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry.

Authors: Fabien Thoreau; Vijay Chudasama
Journal: RSC Chem Biol Date: 2021-10-22